Download PDF
Open Access
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(04): 213-218
DOI: 10.1590/0004-282X20180023
Article

Amitriptyline and intraoral devices for migraine prevention: a randomized comparative trial

Amitriptilina e dispositivos intraorais para a prevenção da migrânea: estudo randomizado e comparativo

Authors

  • Marco A. D. Bruno

    1   Universidade Federal Fluminense, Departamento de Neurologia, Niterói RJ, Brasil

  • Abouch V. Krymchantowski

    2   Centro de Avaliação e Tratamento da Dor de Cabeça do Rio de Janeiro, Rio de Janeiro RJ, Brasil
Further Information
Also available at
  Permissions and Reprints
Preview

ABSTRACT

Objectives: Nonpharmacological treatments, such as the Nociceptive Trigeminal Inhibition Tension Suppression System (NTI-tss), are approved for migraine prophylaxis. We aimed at evaluating the effectiveness of the NTI-tss and to compare its efficacy with amitriptyline and with a sham intraoral device in the preventive treatment of migraine.

Methods: Consecutive patients with migraine were randomized to receive 25 mg of amitriptyline/day (n = 34), NTI-tss (n = 33) and a non-occlusal splint (n = 30). The headache frequency was evaluated at six and 12 weeks.

Results: The amitriptyline group showed, respectively, 60% and 64% reduction in attack frequency at six and 12 weeks (P = 0.000). In the NTI-tss and non-occlusal splint groups, reduction was 39% and 30%, respectively, at six weeks and 48% for both groups at 12 weeks.

Conclusions: Amitriptyline proved superior to the NTI-tss and the non-occlusal splint. Despite its approval by the United States Food and Drug Administration, the NTI-tss was not superior to a sham device.

RESUMO

Objetivo: Tratamentos não farmacológicos como o Nociceptive Trigeminal Inhibition Tension Suppression System (NTI-tss), são aprovados para a prevenção da migrânea. Avaliamos a eficácia do NTI-tss no tratamento preventivo da migrânea e comparamos sua eficácia com a de um medicamento tradicional (amitriptilina) e com um dispositivo intraoral que não interfere com a oclusão (placa palatina).

Métodos: Pacientes consecutivos com migrânea foram randomizados e receberam 25mg de amitriptilina/dia (n = 34), NTI-tss (n = 33) ou placa palatina não oclusal (n = 30). A frequência da cefaleia foi comparada após seis e 12 semanas.

Resultados: No grupo da amitriptilina houve redução de 60% em seis semanas e de 64% em 12 semanas (P = 0.000). Nos grupos do NTI-tss e da placa não oclusal a redução foi respectivamente de 39% e 30% após seis semanas, e de 48% para ambos em 12 semanas.

Conclusões: Amitriptilina foi superior ao NTI-tss e à placa palatina no tratamento da migrânea sem aura. O NTI-tss obteve resultados similares aos da placa não oclusal.

Keywords:

migraine disorders - amitriptyline - preventive medicine

Palavras-chave:

transtornos da enxaqueca - amitriptilina - medicina preventiva


Publication History

Received: 12 September 2017

Accepted: 19 January 2018

Article published online:
28 August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 World Health Organization. Atlas of headache disorders and resources in the world. Geneva: WHO; 2011.
  • 2 Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 Mar;27(3):193-210. https://doi.org/10.1111/j.1468-2982.2007.01288.x
  • 3 Spierings EL. Mechanism of migraine and action of antimigraine medications. Med Clin North Am. 2001 Jul;85(4):943-58. https://doi.org/10.1016/S0025-7125(05)70352-7
  • 4 Krymchantowski AV. Combining therapies for the treatment of migraine: is there a role? Expert Rev Neurother. 2005 Mar;5(2):145-7. https://doi.org/10.1586/14737175.5.2.145
  • 5 Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry. 1973 Aug;36(4):684-90. https://doi.org/10.1136/jnnp.36.4.684
  • 6 Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects. Neurology. 1976 Feb;26(2):121-7. https://doi.org/10.1212/WNL.26.2.121
  • 7 Okeson J. Management of temporomandibular disorders and occlusion. 7th ed. St. Louis: Elsevier; 2013.
  • 8 Shankland WE 2nd. Migraine and tension-type headache reduction through pericranial muscular suppression: a preliminary report. Cranio. 2001 Oct;19(4):269-78. https://doi.org/10.1080/08869634.2001.11746178
  • 9 Shankland WE. Nociceptive trigeminal inhibition: tension suppression system: a method of preventing migraine and tension headaches. Compend Contin Educ Dent. 2002 Feb;23(2):105-8.
  • 10 Ekberg E, Vallon D, Nilner M. Treatment outcome of headache after occlusal appliance therapy in a randomized controlled trial among patients with TMDs of mainly arthrogenous origen. Swed Dent J. 2002;26(3):115-24.
  • 11 Jokstad A, Mo A, Krogstad BS. Clinical comparison between two different splint designs for temporomandibular disorder therapy. Acta Odontol Scand. 2005 Aug;63(4):218-26. https://doi.org/10.1080/00016350510019982
  • 12 Stapelmann H, Türp JC. The NTI-tss device for the therapy of bruxism, temporomandibular disorders, and headache: where do we stand? A qualitative systematic review of the literature. BMC Oral Health. 2008 Jul;8(1):22. https://doi.org/10.1186/1472-6831-8-22
  • 13 Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. J Craniomandib Disord. 1992;6(4):301-55.
  • 14 The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24 Suppl 1:9-160.
  • 15 Burch R, Wells R. Pathophysiology of migraine. Headache. 2013 Feb;53(2):420-2. https://doi.org/10.1111/head.12027
  • 16 Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep. 2011 Apr;11(2):139-48. https://doi.org/10.1007/s11910-010-0175-6
  • 17 Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol. 2017 Sep;264(9):2031-9. https://doi.org/10.1007/s00415-017-8434-y
  • 18 Drummond PD, Lance JW. Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol. 1983 Jan;13(1):32-7. https://doi.org/10.1002/ana.410130108
  • 19 Wright EF, Jundt JS. The NTI appliance for TMD and headache therapy. Tex Dent J. 2006 Dec;123(12):1118-24.
  • 20 May BM, Garabadian C. Reducing condylar compression in clenching patients. Crit Rev Biomed Eng. 2000;28(3-4):389-94. https://doi.org/10.1615/CritRevBiomedEng.v28.i34.70
  • 21 Becker I, Tarantola G, Zambrano J, Spitzer S, Oquendo D. Effect of a prefabricated anterior bite stop on electromyographic activity of masticatory muscles. J Prosthet Dent. 1999 Jul;82(1):22-6. https://doi.org/10.1016/S0022-3913(99)70127-7
  • 22 Baad-Hansen L, Jadidi F, Castrillon E, Thomsen PB, Svensson P. Effect of a nociceptive trigeminal inhibitory splint on electromyographic activity in jaw closing muscles during sleep. J Oral Rehabil. 2007 Feb;34(2):105-11. https://doi.org/10.1111/j.1365-2842.2006.01717.x
  • 23 Ciancaglini R, Radaelli G. The relationship between headache and symptoms of temporomandibular disorder in the general population. J Dent. 2001 Feb;29(2):93-8. https://doi.org/10.1016/S0300-5712(00)00042-7
  • 24 Ballegaard V, Thede-Schmidt-Hansen P, Svensson P, Jensen R. Are headache and temporomandibular disorders related? A blinded study. Cephalalgia. 2008 Aug;28(8):832-41. https://doi.org/10.1111/j.1468-2982.2008.01597.x
  • 25 Gonçalves DA, Speciali JG, Jales LC, Camparis CM, Bigal ME. Temporomandibular symptoms, migraine, and chronic daily headaches in the population. Neurology. 2009 Aug;73(8):645-6. https://doi.org/10.1212/WNL.0b013e3181b389c2
  • 26 Franco AL, Gonçalves DA, Castanharo SM, Speciali JG, Bigal ME, Camparis CM. Migraine is the most prevalent primary headache in individuals with temporomandibular disorders. J Orofac Pain. 2010;24(3):287-92.
  • 27 Klasser GD, Greene CS. Oral appliances in the management of temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Feb;107(2):212-23. https://doi.org/10.1016/j.tripleo.2008.10.007
  • 28 Wright EF. Manual of temporomandibular disorders. 2nd ed. Amis: Wiley-Blackwell, 2010.
  • 29 Stohler CS. Interocclusal appliances: do they offer a biologic advantage? In: McNeill C, editor. Science and practice of occlusion. Chicago: Quintessence; 1997. p. 381-93.
  • 30 Tfelt-Hansen PC, Hougaard A. Migraine: differential effects of placebos in migraine clinical trials. Nat Rev Neurol. 2014 Jan;10(1):10-1. https://doi.org/10.1038/nrneurol.2013.255